Novel Transcatheter No-Implant LAA Closure System

90% of strokes in AF patients are caused by migration of blood clots to from the LAA the brain.

Medications are frequently prescribed for AF patients to help prevent blood clots; but a significant proportion of patients do not receive adequate anticoagulant therapy due to increased risk of bleeding.

Device solutions include transcatheter implantable devices for LAA closure, such as Watchman or Amulet.

However, due to the LAA’s complex structure, it is difficult to close it completely using these devices. If incomplete closure occurs, leakage of clots from the LAA to the brain is still possible. In addition, these implanted devices may increase the risk of device-related thromboembolism (DRT).

The LAA closure market potential is estimated to reach $10B within several years, with potential sales of $500M in 2019.

Append Medical’s non-implanted transcatheter LAA exclusion system employs innovative mechanical principles to ensure secure LAA closure by invaginating the LAA and closing it with a snare, leaving no additional implant. Primary advantages over available devices are expected to include ease of implant, complete sealing and significantly reduced risk of device-related thrombosis.

First prototype tested in ex vivo human hearts | Ongoing clinical safety trial showing positive interim results | Currently: In vivo trials

Patent granted in US and Israel, licensed from Sheba Medical Center
Patent National covering the main concepts of LAA invagination

Provisional – LAA Tissue Manipulation